Evidence map›Paper›PMID 26056443›Full record

ArticleInternational journal of nanomedicine2015

Amino-functionalized poly(L-lactide) lamellar single crystals as a valuable substrate for delivery of HPV16-E7 tumor antigen in vaccine development.

Paola Di Bonito, Linda Petrone, Gabriele Casini, Iolanda Francolini, Maria Grazia Ammendolia, Luisa Accardi, Antonella Piozzi, Lucio D'Ilario, Andrea Martinelli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 20 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Paola Di BonitoDepartment of Infectious, Parasitic and Immune-mediated Diseases, Italian National Institute of Health, Rome, Italy.
Linda PetroneDepartment of Infectious, Parasitic and Immune-mediated Diseases, Italian National Institute of Health, Rome, Italy.
Gabriele CasiniDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Iolanda FrancoliniDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Maria Grazia AmmendoliaDepartment of Technology and Health, Italian National Institute of Health, Rome, Italy.
Luisa AccardiDepartment of Infectious, Parasitic and Immune-mediated Diseases, Italian National Institute of Health, Rome, Italy.
Antonella PiozziDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Lucio D'IlarioDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Andrea MartinelliDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITIstituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoly(L-lactide) (PLLA) is a biodegradable polymer currently used in many biomedical applications, including the production of resorbable surgical devices, porous scaffolds for tissue engineering, nanoparticles and microparticles for the controlled release of drugs or antigens. The surfaces of lamellar PLLA single crystals (PLLAsc) were provided with amino groups by reaction with a multifunctional amine and used to adsorb an Escherichia coli-produced human papillomavirus (HPV)16-E7 protein to evaluate its possible use in antigen delivery for vaccine development.

methodsPLLA single crystals were made to react with tetraethylenepentamine to obtain amino-functionalized PLLA single crystals (APLLAsc). Pristine and amino-functionalized PLLAsc showed a two-dimensional microsized and one-dimensional nanosized lamellar morphology, with a lateral dimension of about 15-20 μm, a thickness of about 12 nm, and a surface specific area of about 130 m(2)/g. Both particles were characterized and loaded with HPV16-E7 before being administered to C57BL/6 mice for immunogenicity studies. The E7-specific humoral-mediated and cell-mediated immune response as well as tumor protective immunity were analyzed in mice challenged with TC-1 cancer cells.

resultsPristine and amino-functionalized PLLAsc adsorbed similar amounts of E7 protein, but in protein-release experiments E7-PLLAsc released a higher amount of protein than E7-APLLAsc. When the complexes were dried for observation by scanning electron microscopy, both samples showed a compact layer, but E7-APLLAsc showed greater roughness than E7-PLLAsc. Immunization experiments in mice showed that E7-APLLAsc induced a stronger E7-specific immune response when compared with E7-PLLAsc. Immunoglobulin G isotyping and interferon gamma analysis suggested a mixed Th1/Th2 immune response in both E7-PLLAsc-immunized and E7-APLLAsc-immunized mice. However, only the mice receiving E7-APLLAsc were fully protected from TC-1 tumor growth after three doses of vaccine.

conclusionOur results show that APLLA single crystals improve the immunogenicity of HPV16-E7 and indicate that E7-APLLAsc could be used for development of an HPV16 therapeutic vaccine against HPV16-related tumors.

Indexed as

AnimalsAntigens, NeoplasmDrug Delivery SystemsEscherichia coliEthylenediaminesFemaleImmunity, CellularImmunizationImmunoglobulin GMiceMice, Inbred C57BLNanoparticlesPapillomavirus E7 ProteinsPapillomavirus VaccinesPolyestersAntigens, NeoplasmEthylenediaminesImmunoglobulin Goncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsPapillomavirus VaccinesPolyesterspoly(lactide)tetraethylenepentamineHPV16-E7human papillomaviruslamellar crystalspoly(l-lactide)therapeutic vaccine

Identifiers

PMID26056443
PMCPMC4431504
OpenAlexW1915243685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.